Blood Advances (BA) is a scholarly journal dedicated to publishing research in the field of Medicine. American Society of Hematology is the publisher of this esteemed journal. The P-ISSN assigned to Blood Advances is 2473-9529 and its abbreviated form is Blood Adv.
Blood Advances publishes more peer-reviewed hematology research than any other academic journal worldwide and is an online only, open-access journal of the American Society of Hematology, the world’s largest professional society concerned with the causes and treatment of blood disorders. The journal is continuously published, meaning that new articles are added on a daily basis. With an impact factor of 7.6 (2022), Blood Advances publishes original research, unique digital content including Blood Advances Talks audio reviews, and important community resources such as the ASH Clinical Guidelines.
Blood Advances provides an international forum for the publication of original articles describing basic laboratory, translational, and clinical investigations in hematology. The journal covers all aspects of hematology, including disorders of leukocytes, both benign and malignant, erythrocytes, platelets, hemostatic mechanisms, vascular biology, immunology, and hematologic oncology. All articles undergo a rigorous peer-review and are selected on the basis of the originality of the findings, the superior quality of the work described, and the clarity of presentation.
|Journal title||Blood Advances (BA)|
|Publisher Name||American Society of Hematology|
|Editor-in-chief||Catherine M. Bollard, MD|
Blood Advances Abbreviation : ISO Journal abbreviation refers to the shortened form or acronym used to represent the full title of a scholarly journal. The ISO4 Abbreviation of Blood Advances Journal is Blood Adv.
The Ranking of Blood Advances in 2023 is 589. Ranking systems aim to provide an indication of a journal's quality, influence, and prestige within a specific field or discipline.
The Impact Factor of Blood Advances in 2023 is 7.5. it is all calculated by Clarivate, which means how many times a particular citation has been published in the past two years.
The SCImago of Blood Advances in 2023 is 3.070. It is measured by the number of citations which are made by the particular journals, and the journal from where the citations arrived from.
The H-Index of Blood Advances in 2023 is 69. The H-index is calculated on how many times a particular author is cited and the number of published papers that a particular author has.
The Quartile of Blood Advances is Q1. A quartile has three points, which are the upper quartile, median, and lower quartile. The main motive of the quartile is to calculate the interquartile range, that resembles the changes across the median.
The Blood Advances is indexed in (Indexing details)
|PubMed||Scopus||Web of Science||UGC||Embase||DOAJ|
Indexing services aim to make it easier for researchers, scholars, and readers to discover and access articles from various journals within a specific field or discipline.
|Access type||Open Access|
The Editor-in-chief of Blood Advances is Catherine M. Bollard, MD
Blood Advances Processing/Submission Fee : Article submission/Processing fees (APC), also known as manuscript Publication fees or processing fees (APC), are charged by journals to authors for submitting/publishing their research papers/article.
The APC/Submission (Publication) Fee of Blood Advances is 3000 USD, 2740 EUR, 2400 GBP
Blood Advances Call for paper : Blood Advances invites original research contributions for consideration of publication in Blood Advances journal.
Journal seeking submissions in the broad areas of Medicine that align with journal's focus on Medicine.
for details about call for paper please visit to the official website of the journal to check the details about call for papers.
Publishing in Blood Advances involves the following steps:
Yes, the Blood Advances journal is indexed in PubMed.
Yes, the Blood Advances journal is indexed in Scopus.
Yes, the Blood Advances journal is indexed in UGC.
No, the Blood Advances journal is not indexed in Index copernicus.
No, Blood Advances journal is not a predatory journal.
The Impact Factor of the Blood Advances is 7.5.
The Ranking of the Blood Advances is 589.
Yes the Blood Advances (BA) journal is a peer-reviewed journal.
Yes the Blood Advances journal is a peer-reviewed journal and good to publish your paper.
Yes, Blood Advances is a open access journal.